Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms

Blood

Volumn 121, Issue 21, 2013, Pages 4388-4395

  Rumi, Elisa ^a,b   Pietra, Daniela ^b   Guglielmelli, Paola ^c   Bordoni, Roberta ^d   Casetti, Ilaria ^a   Milanesi, Chiara ^b   Sant’Antonio, Emanuela ^a   Ferretti, Virginia ^b   Pancrazzi, Alessandro ^c   Rotunno, Giada ^c   Severgnini, Marco ^d   Pietrelli, Alessandro ^d   Astori, Cesare ^b   Fugazza, Elena ^b   Pascutto, Cristiana ^b   Boveri, Emanuela ^b   Passamonti, Francesco ^e   De Bellis, Gianluca ^d   Vannucchi, Alessandro ^c   Cazzola, Mario ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; THROMBOPOIETIN RECEPTOR; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN;

ALLELE; ARTICLE; CHROMOSOME 1P; CODON; COHORT ANALYSIS; EXON; GENE MUTATION; GENE SEQUENCE; GRANULOCYTE; HETEROZYGOSITY LOSS; HIGH RESOLUTION MELTING ANALYSIS; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; PHENOTYPE; PRIORITY JOURNAL; SOMATIC MUTATION; THROMBOCYTHEMIA; ADOLESCENT; ADULT; AGED; BONE MARROW; CHROMOSOME 1; FEMALE; FIBROSIS; GENE DOSAGE; GENETICS; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDER; PATHOLOGY; PHYSIOLOGY; STATISTICAL MODEL; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; CHROMOSOMES, HUMAN, PAIR 1; FEMALE; FIBROSIS; GENE DOSAGE; GRANULOCYTES; HUMANS; INCIDENCE; JANUS KINASE 2; LOGISTIC MODELS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880595307     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-486050     Document Type: Article

References (42)

1. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med. 2006;355(23): 2452-2466.
2. Baxter EJ, Scott LM, Campbell PJ, et al; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
3. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397.
4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005; 352(17):1779-1790.
5. James C, Ugo V, Le Couédic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037): 1144-1148.
6. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
7. Pardanani AD, Levine RL, Lasho T, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-3476.
8. Guglielmelli P, Pancrazzi A, Bergamaschi G, et al; GIMEMA–Italian Registry of Myelofibrosis; MPD Research Consortium. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137(3):244-247.
9. Beer PA, Campbell PJ, Scott LM, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008;112(1):141-149.
10. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W.L/K mutation in essential thrombocythemia. Blood. 2008;112(3):844-847.
11. Boyd EM, Bench AJ, Goday-Fernández A, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis. Br J Haematol. 2010; 149(2):250-257.
12. Pardanani A, Guglielmelli P, Lasho TL, Pancrazzi A, Finke CM, Vannucchi AM, Tefferi A. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011;25(12): 1834-1839.
13. Pietra D, Brisci A, Rumi E, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-611.
14. Schnittger S, Bacher U, Eder C, et al. Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow. Haematologica. 2012;97(10):1582-1585.
15. Brisci A, Damin F, Pietra D, et al. COLD-PCR and innovative microarray substrates for detecting and genotyping MPL exon 10 W515 substitutions. Clin Chem. 2012;58(12):1692-1702.
16. Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200.
17. Chaligné R, Tonetti C, Besancenot R, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8):1557-1566.
18. Rumi E, Harutyunyan A, Elena C, et al. Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm. Am J Hematol. 2011;86(12):974-979.
19. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD341 cells into peripheral blood in myeloproliferative disorders. Blood. 2006; 107(9):3676-3682.
20. Vannucchi AM, Antonioli E, Guglielmelli P, et al; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. Leukemia. 2007;21(9):1952-1959.
21. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
22. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7): 2292-2302.
23. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008.
24. Barosi G, Mesa RA, Thiele J, et al; International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437-438.
25. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8): 1128-1132.
26. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
27. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6): 761-770.
28. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17): 3538-3545.
29. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New YorK: Wiley; 1980.
30. O’Keefe C, McDevitt MA, Maciejewski JP. Copy neutral loss of heterozygosity: a novel chromosomal lesion in myeloid malignancies. Blood. 2010;115(14):2731-2739.
31. Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006;107(5):1864-1871.
32. Campbell PJ, Scott LM, Buck G, et al; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953.
33. Cazzola M, Skoda R. Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica. 2005;90(7):871-874.
34. Godfrey AL, Chen E, Pagano F, et al. JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Blood. 2012;120(13):2704-2707.
35. Szpurka H, Gondek LP, Mohan SR, Hsi ED, Theil KS, Maciejewski JP. UPD1p indicates the presence of MPL W515L mutation in RARS-T, a mechanism analogous to UPD9p and JAK2 V617F mutation. Leukemia. 2009;23(3): 610-614.
36. Grand FH, Hidalgo-Curtis CE, Ernst T, et al. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood. 2009;113(24):6182-6192.
37. Jones AV, Campbell PJ, Beer PA, et al. The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010; 115(22):4517-4523.
38. Qian H, Buza-Vidas N, Hyland CD, et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell. 2007;1(6):671-684.
39. Chaligné R, James C, Tonetti C, et al. Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood. 2007; 110(10):3735-3743.
40. Pecquet C, Staerk J, Chaligné R, et al. Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood. 2010; 115(5):1037-1048.
41. Ciurea SO, Merchant D, Mahmud N, et al. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007;110(3): 986-993.
42. Balduini A, Badalucco S, Pugliano MT, et al. In vitro megakaryocyte differentiation and proplatelet formation in Ph-negative classical myeloproliferative neoplasms: distinct patterns in the different clinical phenotypes. PLoS ONE. 2011;6(6):e21015.